Xeris Biopharma Holdings Inc
XERS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.86B
Close$
$2.89
71.7% downside
Current Fair Value
71.7% downsideOvervalued by 71.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.86 Billion |
|---|---|
| Enterprise Value | $2.03 Billion |
| Earnings per Share | $0 |
| Beta | 0.84 |
| Outstanding Shares | 172,823,455 |
Return
| Return on Equity | 176.34% |
|---|---|
| Return on Assets | -4.17% |
| Return on Invested Capital | 0.71% |
Valuation & Multiples
| P/E Ratio | -105.05 |
|---|---|
| PEG | -6.94 |
| Price to Sales | 10.21 |
| Price to Book Ratio | -10.21 |
| Enterprise Value to Revenue | 6.05 |
| Enterprise Value to EBIT | 1290.23 |
| Enterprise Value to Net Income | -119 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -29.74 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$90.13 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.03
Consensus analyst estimateRevenue Estimate
$101.68 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 64.35% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.34%▼ 62.16% |
|---|---|
| Total Invested | $22.36M▼ 97.43% |
| Investors Holding | 24▼ 227.00% |
About Xeris Pharmaceuticals Inc
435 employees
CEO: paul Edick
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and ...